Biotech and Pharma

Tesla stock extends gains as it appears the feud between CEO Elon Musk and President Donald Trump is cooling, while GameStop is scheduled to report first-quarter earnings Tuesday.

The head of the Department of Health and Human Services fired all the members of a committee advising the CDC on vaccine policy.

The company reports the results of a Phase 2b study for a drug meant to treat pulmonary arterial hypertension.

Investors will be waiting for news on how the makeup of a reconstituted ACIP will look like.

Apple’s artificial intelligence projects, L.A. protesters target Waymo driverless cars, RFK Jr. fires vaccine advisory board, and more news to start your day.

He said the Department of Health and Human Services is “putting the restoration of public trust above any pro- or antivaccine agenda,” in an op-ed in The Wall Street Journal.

The medication could face competition from AstraZeneca, which is testing a different oral PSCK9 inhibitor.

Inflation data this week, Tesla’s robotaxi launch, the Berkshire Hathaway wannabes, and more news to start your day.

Vera Therapeutics stock rocketed nearly 70% on Monday on upbeat data for a kidney-disease trial. Shares are tumbling Friday on a rival’s study.

U.S. drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be worth up to $25 billion.

Shares of the biotech Kymera Therapeutics are up 50% since Monday.

By selling call options, you can get paid to cull underperformers from your portfolio.

Nvidia is on pace to overtake Microsoft as the largest U.S. company by market cap.

Hims agreed to buy private European telehealth firm Zava, which operates in the U.K., Germany, France, and Ireland.

Merck submitted a nonbinding offer for the smaller biotech earlier in the year, according to a media report citing people familiar with the matter.

The dollar’s worst start to a year on record, Bristol Myers plans to develop new cancer drug, Apple’s WWDC is coming, and more news to start your day.

Drugmakers hope a new class of cancer drugs could unseat Keytruda, the Merck immuno-oncology blockbuster.

The deal announced Monday is Sanofi's third of the year so far.

Moderna said mNEXSPIKE was approved by the FDA for use in adults aged 65 and up, as well as some individuals aged 12 to 64.

Its dermatitis drug could win at least 10% of annual sales in dermatitis by 2030—or about $3 billion.

The CDC’s new Covid-19 recommendations are the first time that Robert F. Kennedy Jr. has narrowed access to vaccines in the U.S.

Partners Regeneron and Sanofi say itepekimab only achieved a significantly statistic result in one of two studies.

The trial was meant to answer the biggest question in biotech: What happens when U.S. companies test promising new Chinese cancer immunotherapies in western countries?

Tariffs are in limbo after court ruling, Powell emphasizes Fed independence, more retail earnings, and more news to start your day.

Successful trial results in the next few years could save thousands of lives and generate billions in new annual revenue for drugmakers.